연속 혈당 모니터링 시스템 시장 : 제품별, 기술별, 최종 사용자별, 유통 채널별, 용도별 예측(2026-2032년)

The Continuous Blood Glucose Monitoring Systems Market is projected to grow by USD 35.92 billion at a CAGR of 13.33% by 2032.

Continuous Blood Glucose Monitoring Systems Market Introduction

Continuous blood glucose monitoring systems have moved from specialty diabetes technology to a core component of modern diabetes management. The market is supported by a large and growing clinical need: the International Diabetes Federation reported 537 million adults living with diabetes in 2021 and projects 643 million by 2030, increasing demand for real-time glucose data, therapy optimization, and remote monitoring.

CGM adoption is being reinforced by sensor miniaturization, smartphone connectivity, interoperable insulin delivery, and stronger payer recognition of time-in-range as a meaningful care metric. For manufacturers, providers, and payers, the opportunity is no longer limited to Type 1 diabetes; it increasingly spans insulin-treated Type 2 diabetes, pregnancy-related diabetes, hospital glucose management, and preventive metabolic health programs.

Transformative Shifts in the CGM Landscape

The CGM landscape is shifting from episodic fingerstick testing toward continuous, connected, and predictive diabetes care. FDA-cleared integrated CGM platforms, expanding automated insulin delivery ecosystems, and longer-wear sensors are improving patient convenience while generating clinically actionable glucose trend data.

Commercial transformation is also accelerating. Reimbursement expansion in the United States, NICE-backed access pathways in the United Kingdom, and growing digital health investment in Asia-Pacific are widening eligibility. At the same time, competition is increasing around sensor accuracy, wear duration, affordability, interoperability, and data services, pushing companies to differentiate through outcomes rather than hardware alone.

Cumulative Impact of Artificial Intelligence on CGM

Artificial intelligence is becoming a practical layer in continuous glucose monitoring, not a distant concept. Machine learning models can detect glucose patterns, flag hypoglycemia risk, personalize alerts, and support insulin dosing decisions when used within regulated clinical workflows. These capabilities are especially valuable because CGM produces high-frequency longitudinal data that traditional blood glucose meters cannot provide.

The cumulative impact of AI is expected to be strongest where CGM data integrates with electronic health records, virtual care platforms, and automated insulin delivery systems. However, industry leaders must manage algorithm transparency, cybersecurity, clinical validation, and bias risks to maintain trust with regulators, clinicians, and patients.

Key Regional Insights for CGM Adoption

North America remains the most mature CGM market, led by the United States, where CDC data show 38.4 million people had diabetes in 2021 and payer coverage has expanded for insulin-treated patients. Canada benefits from provincial reimbursement progress, specialist diabetes networks, and high digital health readiness.

Europe is shaped by structured reimbursement, strong regulatory oversight under the Medical Device Regulation, and clinical guidance from national health systems, while the European Union supports cross-border digital health standards. Asia-Pacific is an expanding opportunity, driven by China and India's large diabetes populations, Japan and South Korea's advanced medtech infrastructure, and Australia's public subsidy mechanisms.

Latin America, the Middle East, and Africa are earlier-stage but increasingly relevant. Brazil and Mexico are building demand through private care and urban diabetes clinics; GCC countries are investing in chronic disease management; and African adoption is concentrated in private healthcare, donor-supported programs, and major urban centers where affordability remains the central constraint.

Key Economic and Strategic Group Insights

Within ASEAN, CGM adoption is rising alongside diabetes screening, private hospital expansion, and mobile-first healthcare delivery, although reimbursement and affordability vary widely by country. GCC markets are supported by high diabetes prevalence, national digital health strategies, and premium hospital systems that can implement connected monitoring at scale.

The European Union offers a structured environment for CGM through regulatory harmonization, health technology assessment, and procurement discipline, while BRICS countries represent high-volume growth potential because of large diabetes populations and expanding middle-class access. G7 markets remain innovation leaders due to advanced reimbursement, clinical research capacity, and established medtech distribution.

NATO member countries, many of which overlap with G7 and EU economies, provide strong infrastructure for digital health security, clinical data governance, and resilient medical supply chains. Across these groups, the leading commercial theme is balancing access expansion with evidence requirements for outcomes, cost-effectiveness, and patient adherence.

Key Country Insights Across Major CGM Markets

The United States leads global CGM commercialization through FDA-cleared innovation, broad specialist adoption, and expanded Medicare coverage for qualifying insulin-treated patients and some people with problematic hypoglycemia. Canada is advancing through provincial reimbursement and diabetes technology programs, while Mexico and Brazil show growing private-sector demand supported by rising diabetes burden and urban specialty care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from national health systems, clinical guidelines, and reimbursement pathways, though access levels differ by region and patient category. Russia's market is influenced by public procurement, import dynamics, local registration requirements, and specialist care availability.

China and India represent the largest long-term volume opportunities because of their diabetes populations, but affordability, reimbursement, physician awareness, and distribution remain decisive. Japan, South Korea, and Australia offer advanced regulatory systems, strong clinician engagement, and high acceptance of connected medical devices, making them important markets for premium sensors, integrated insulin delivery, and data-driven diabetes services.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that links CGM use to reduced hypoglycemia, improved time-in-range, lower acute care utilization, and better patient quality of life. Strong real-world evidence is essential for payer negotiations, guideline inclusion, and broader access among Type 2 diabetes populations.

Companies should also design for affordability, interoperability, and adherence. Strategic actions include building partnerships with insulin pump manufacturers, telehealth providers, pharmacies, and health systems; localizing pricing in emerging markets; strengthening cybersecurity; and simplifying onboarding so patients can consistently use CGM data in daily decision-making.

Research Methodology

This executive summary is developed using a secondary research-led methodology aligned with healthcare market intelligence standards. Inputs include public data from the International Diabetes Federation, World Health Organization, CDC, FDA, CMS, NICE, national health ministries, peer-reviewed diabetes journals, regulatory databases, and established medtech disclosures.

The analysis triangulates epidemiology, reimbursement policy, regulatory approvals, clinical adoption indicators, technology trends, and regional healthcare infrastructure. Findings emphasize verified, publicly available evidence and avoid unsupported market-size claims, ensuring that insights remain suitable for executive planning, SEO-led web publishing, and strategic decision support.

Conclusion

Continuous blood glucose monitoring systems are reshaping diabetes care by replacing intermittent testing with continuous, connected, and increasingly predictive insight. The market is being strengthened by rising diabetes prevalence, broader reimbursement, sensor innovation, AI-enabled analytics, and integration with automated insulin delivery.

Future leadership will depend on more than device accuracy. Organizations that prove clinical and economic value, protect patient data, improve affordability, and support seamless care workflows will be best positioned to capture growth across mature markets and high-potential emerging economies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Continuous Blood Glucose Monitoring Systems Market, by Product

• 7.1. Data Management Software & Services
  • 7.1.1. Data Management Software
  • 7.1.2. Support Services
• 7.2. Sensor
• 7.3. Transmitter & Receiver

8. Continuous Blood Glucose Monitoring Systems Market, by Technology

• 8.1. Real Time CGM
  • 8.1.1. Personal Real Time CGM
  • 8.1.2. Professional Real Time CGM
• 8.2. Retrospective CGM

9. Continuous Blood Glucose Monitoring Systems Market, by End User

• 9.1. Ambulatory Care Centers
  • 9.1.1. Diagnostic Centers
  • 9.1.2. Surgery Centers
• 9.2. Home Care
• 9.3. Hospitals & Clinics
  • 9.3.1. Clinics
  • 9.3.2. Hospitals

10. Continuous Blood Glucose Monitoring Systems Market, by Distribution Channel

• 10.1. Hospital Pharmacies
• 10.2. Online Pharmacies
  • 10.2.1. E Commerce Websites
  • 10.2.2. Manufacturer Websites
• 10.3. Retail Pharmacies
  • 10.3.1. Chain Pharmacies
  • 10.3.2. Independent Pharmacies

11. Continuous Blood Glucose Monitoring Systems Market, by Application

• 11.1. Type 1 Diabetes
• 11.2. Type 2 Diabetes

12. Continuous Blood Glucose Monitoring Systems Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Continuous Blood Glucose Monitoring Systems Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Continuous Blood Glucose Monitoring Systems Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. A. Menarini Diagnostics s.r.l
• 16.2. Abbott Laboratories
• 16.3. AgaMatrix Inc. by I-Sens Inc.
• 16.4. ARKRAY, Inc.
• 16.5. Ascensia Diabetes Care Holdings AG
• 16.6. Dexcom, Inc.
• 16.7. F. Hoffmann-La Roche Ltd
• 16.8. Insulet Corporation
• 16.9. Johnson & Johnson Services, Inc.
• 16.10. Medtronic PLC
• 16.11. Medtrum Technologies Inc.
• 16.12. Nemaura Medical Inc.
• 16.13. Nipro Corporation
• 16.14. Novo Nordisk A/S
• 16.15. NXP Semiconductors N.V.
• 16.16. Senseonics Holdings Inc.
• 16.17. Sibionics
• 16.18. Sinocare Inc.
• 16.19. STMicroelectronics N.V.
• 16.20. Tandem Diabetes Care, Inc.
• 16.21. Texas Instruments Incorporated
• 16.22. Ypsomed Holding AG